Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 145.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,818 shares of the company’s stock after purchasing an additional 4,035 shares during the quarter. Migdal Insurance & Financial Holdings Ltd.’s holdings in Eli Lilly And Co were worth $732,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. FMR LLC grew its holdings in Eli Lilly And Co by 172.9% during the 2nd quarter. FMR LLC now owns 1,188,301 shares of the company’s stock valued at $101,398,000 after buying an additional 752,864 shares in the last quarter. Balasa Dinverno & Foltz LLC grew its holdings in Eli Lilly And Co by 15.9% during the 3rd quarter. Balasa Dinverno & Foltz LLC now owns 3,629 shares of the company’s stock valued at $389,000 after buying an additional 499 shares in the last quarter. We Are One Seven LLC purchased a new position in Eli Lilly And Co during the 3rd quarter valued at approximately $1,084,000. First American Bank purchased a new position in Eli Lilly And Co during the 3rd quarter valued at approximately $7,863,000. Finally, Greenleaf Trust grew its holdings in Eli Lilly And Co by 37.7% during the 2nd quarter. Greenleaf Trust now owns 9,815 shares of the company’s stock valued at $838,000 after buying an additional 2,686 shares in the last quarter. Hedge funds and other institutional investors own 76.91% of the company’s stock.

Several equities analysts have weighed in on the company. Cantor Fitzgerald set a $100.00 price target on Eli Lilly And Co and gave the company a “buy” rating in a report on Tuesday, July 24th. ValuEngine upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating in a report on Monday, November 12th. Societe Generale set a $106.00 price target on Eli Lilly And Co and gave the company a “hold” rating in a report on Wednesday, November 7th. BMO Capital Markets raised their price target on Eli Lilly And Co from $80.00 to $90.00 and gave the company a “market perform” rating in a report on Wednesday, July 25th. They noted that the move was a valuation call. Finally, Barclays raised their price target on Eli Lilly And Co from $112.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, October 12th. Eight investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Eli Lilly And Co has an average rating of “Buy” and an average price target of $111.19.

Shares of Eli Lilly And Co stock opened at $114.72 on Wednesday. The company has a market capitalization of $122.68 billion, a PE ratio of 26.80, a P/E/G ratio of 1.81 and a beta of 0.29. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53. Eli Lilly And Co has a one year low of $73.69 and a one year high of $116.61.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, topping the Zacks’ consensus estimate of $1.35 by $0.04. The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The company’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.05 EPS. As a group, research analysts forecast that Eli Lilly And Co will post 5.58 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be issued a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a dividend yield of 1.96%. The ex-dividend date is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is 52.57%.

In other news, major shareholder Eli & Co Lilly sold 700,000 shares of Eli Lilly And Co stock in a transaction that occurred on Tuesday, November 6th. The stock was sold at an average price of $14.00, for a total value of $9,800,000.00. Following the completion of the transaction, the insider now owns 3,148,647 shares in the company, valued at approximately $44,081,058. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of Eli Lilly And Co stock in a transaction that occurred on Monday, November 19th. The stock was sold at an average price of $115.31, for a total value of $22,485,450.00. Following the completion of the transaction, the insider now owns 118,505,584 shares of the company’s stock, valued at approximately $13,664,878,891.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,127,900 shares of company stock valued at $165,108,695. Company insiders own 0.11% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Eli Lilly And Co (LLY) Shares Bought by Migdal Insurance & Financial Holdings Ltd.” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/11/21/eli-lilly-and-co-lly-shares-bought-by-migdal-insurance-financial-holdings-ltd.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: What is the yield curve?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.